Literature DB >> 27691378

Antidepressant Medication Prescribing Practices for Treatment of Major Depressive Disorder.

Lara A Treviño1, Matthew W Ruble1, Kenneth Treviño1, Lawrence M Weinstein1, Dana P Gresky1.   

Abstract

OBJECTIVE: The purpose of this study was to describe the prescribing practices of clinicians for patients with major depressive disorder (MDD).
METHODS: This population-based, descriptive study of insured patients (N=54,107) identified people who were 18 years or older, had a claim for MDD, had at least one prescription for an antidepressant medication in 2013, and had continuous insurance coverage during the study period. Prescription claims were evaluated to determine the most commonly prescribed antidepressant medication and most common dose.
RESULTS: The three most commonly prescribed antidepressant medications were citalopram (N=11,995, 22.2%), sertraline (N=10,791, 19.9%), and trazodone (N=9,501, 17.6%). The most common daily doses were 20 mg citalopram (N=6,304, 52.6%), 50 mg sertraline (N=4,173, 38.7%), and 100 mg trazodone (N=3,220, 33.9%).
CONCLUSIONS: This is the first report of its kind that provides drug- and dosage-level details to demonstrate that antidepressant prescribing in clinical practice is largely within recommended guidelines.

Entities:  

Keywords:  Antidepressants; Depression; Treatment guidelines

Mesh:

Substances:

Year:  2016        PMID: 27691378     DOI: 10.1176/appi.ps.201600087

Source DB:  PubMed          Journal:  Psychiatr Serv        ISSN: 1075-2730            Impact factor:   3.084


  9 in total

1.  Cost-Effectiveness of Esketamine Nasal Spray for Patients With Treatment-Resistant Depression in the United States.

Authors:  Eric L Ross; Djøra I Soeteman
Journal:  Psychiatr Serv       Date:  2020-07-07       Impact factor: 3.084

2.  ABCB1 variants and sex affect serotonin transporter occupancy in the brain.

Authors:  Leo R Silberbauer; Lucas Rischka; Chrysoula Vraka; Annette M Hartmann; Godber Mathis Godbersen; Cécile Philippe; Daniel Pacher; Lukas Nics; Manfred Klöbl; Jakob Unterholzner; Thomas Stimpfl; Wolfgang Wadsak; Andreas Hahn; Marcus Hacker; Dan Rujescu; Siegfried Kasper; Rupert Lanzenberger; Gregor Gryglewski
Journal:  Mol Psychiatry       Date:  2022-09-07       Impact factor: 13.437

3.  The Cost-Effectiveness of Cognitive Behavioral Therapy Versus Second-Generation Antidepressants for Initial Treatment of Major Depressive Disorder in the United States: A Decision Analytic Model.

Authors:  Eric L Ross; Sandeep Vijan; Erin M Miller; Marcia Valenstein; Kara Zivin
Journal:  Ann Intern Med       Date:  2019-10-29       Impact factor: 25.391

4.  Sertraline induces DNA damage and cellular toxicity in Drosophila that can be ameliorated by antioxidants.

Authors:  Arpita Jajoo; Catherine Donlon; Sarah Shnayder; Michael Levin; Mitch McVey
Journal:  Sci Rep       Date:  2020-03-11       Impact factor: 4.379

5.  Hypersensitivity of Zebrafish htr2b Mutant Embryos to Sertraline Indicates a Role for Serotonin Signaling in Cardiac Development.

Authors:  Mitchell E Kent; Bo Hu; Timothy M Eggleston; Ryan S Squires; Kathy A Zimmerman; Robert M Weiss; Robert D Roghair; Fang Lin; Robert A Cornell; Sarah E Haskell
Journal:  J Cardiovasc Pharmacol       Date:  2022-08-01       Impact factor: 3.271

6.  Concordance of the treatment patterns for major depressive disorders between the Canadian Network for Mood and Anxiety Treatments (CANMAT) algorithm and real-world practice in China.

Authors:  Lu Yang; Yousong Su; Sijia Dong; Tao Wu; Yongjing Zhang; Hong Qiu; Wenjie Gu; Hong Qiu; Yifeng Xu; JianLi Wang; Jun Chen; Yiru Fang
Journal:  Front Pharmacol       Date:  2022-08-31       Impact factor: 5.988

7.  Prescribing behavior of antidepressants for depressive disorders: A systematic review.

Authors:  Mary K Lam; Lawrence T Lam; Kerryn Butler-Henderson; Jonathan King; Tahnee Clark; Peta Slocombe; Katherine Dimarco; Wendell Cockshaw
Journal:  Front Psychiatry       Date:  2022-09-09       Impact factor: 5.435

8.  Effect of fecal microbiota transplant on symptoms of psychiatric disorders: a systematic review.

Authors:  Arthi Chinna Meyyappan; Evan Forth; Caroline J K Wallace; Roumen Milev
Journal:  BMC Psychiatry       Date:  2020-06-15       Impact factor: 3.630

9.  Sahaj Samadhi meditation vs a Health Enhancement Program in improving late-life depression severity and executive function: study protocol for a two-site, randomized controlled trial.

Authors:  Stephen Benjamin Peckham; Emily Ionson; Marouane Nassim; Kevin Ojha; Lena Palaniyappan; Joe Gati; Jean Thebérge; Andrea Lazosky; Mark Speechley; Imants Barušs; Soham Rej; Akshya Vasudev
Journal:  Trials       Date:  2019-10-24       Impact factor: 2.279

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.